Jump Financial LLC Sells 2,458 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jump Financial LLC cut its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 58,308 shares of the biotechnology company’s stock after selling 2,458 shares during the period. Jump Financial LLC owned approximately 0.22% of Arcturus Therapeutics worth $989,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ARCT. Wellington Management Group LLP lifted its position in Arcturus Therapeutics by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock valued at $1,647,000 after acquiring an additional 742 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Arcturus Therapeutics by 22.7% in the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after buying an additional 2,036 shares in the last quarter. Nordea Investment Management AB raised its position in Arcturus Therapeutics by 3.7% in the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock worth $1,097,000 after buying an additional 2,335 shares during the last quarter. Geode Capital Management LLC lifted its stake in Arcturus Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company’s stock valued at $9,421,000 after acquiring an additional 3,186 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Arcturus Therapeutics by 45.0% during the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 3,705 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

ARCT opened at $10.53 on Monday. The firm has a market cap of $285.57 million, a P/E ratio of -4.74 and a beta of 3.41. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $45.00. The company has a 50 day simple moving average of $13.26 and a two-hundred day simple moving average of $16.38.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The business had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. Equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ARCT. Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the company a “buy” rating in a report on Monday, March 10th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Wells Fargo & Company cut their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.